Aardvark Therapeutics Inc. XNAS: AARD

11.61 -0.50 (-4.13%)

40.70% Fall from 52W High

40,020

XNAS Volume

XNAS 15 Jul, 2025 5:30 PM (EDT)

Board Meeting

The next board meeting for Aardvark Therapeutics Inc. is on 16 Jul 2025 for the purpose of Aardvark Therapeutics Inc Annual General Meeting for 2025 See details

Insider Trading disclosures for Aardvark Therapeutics Inc.

The latest disclosure was made by Susan E. Graf in Aardvark Therapeutics Inc. where a trade of 30,508 Stock Option (right to buy) done was reported to US exchanges on June 11, 2025.

Insider trading is the trading of a company’s securities by individuals with access to confidential or material non-public information about the company. A company is required to report trading by corporate officers, directors, or other company members with significant access to privileged information to the Securities and Exchange Commission (SEC).

Client Name	Client Category	Action	Reported to Exchange	Quantity	Post Transaction Holding	Traded %	Avg. Price	Value	Security Type
Susan E. Graf	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	30,508	30,508	-		-	Stock Option (right to buy)
Tien-Li Lee	Director, Chief Executive Officer, Ten Percent Owner	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	549,534	549,534	-		-	Stock option (right to buy)
Roy D. Baynes	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	30,508	30,508	-		-	Stock Option (right to buy)
Jeffrey Chi	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	61,017	61,017	-		-	Stock Option (right to buy)
Victor Tong	Director	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	61,017	61,017	-		-	Stock Option (right to buy)
Manasi Jaiman	Chief Medical Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	126,999	126,999	-		-	Stock Option (right to buy)
Bryan Jones	Chief Operating Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	122,033	122,033	-		-	Stock Option (right to buy)
Nelson Sun	Chief Financial Officer	Grant, award, or other acquisition of securities at price $ 0.00 per share.	11 Jun 2025	209,826	209,826	-		-	Stock Option (right to buy)
Tien-Li Lee	Director, Chief Executive Officer, Ten Percent Owner		14 Feb 2025	350,002	0	-		-	Series A Convertible Preferred Stock
Tien-Li Lee	Director, Chief Executive Officer, Ten Percent Owner		14 Feb 2025	41,303	1,479,633	-		-	Common Stock
Tien-Li Lee	Director, Chief Executive Officer, Ten Percent Owner	Purchase of securities on an exchange or from another person at price $ 16.00 per share.	14 Feb 2025	16,542	1,496,175	-	16	264,672	Common Stock
Jeffrey Chi	Director		14 Feb 2025	133,364	133,364	-		-	Common Stock
Jeffrey Chi	Director		14 Feb 2025	1,130,135	0	-		-	Series C Convertible Preferred Stock
Nelson Sun	Chief Financial Officer	Purchase of securities on an exchange or from another person at price $ 16.00 per share.	14 Feb 2025	10,000	99,484	-	16	160,000	Common Stock
Nelson Sun	Chief Financial Officer		14 Feb 2025	59,332	0	-		-	Series C Convertible Preferred Stock
Nelson Sun	Chief Financial Officer		14 Feb 2025	7,001	89,484	-		-	Common Stock

*All Values are in $ Million

Client Category: Promoter/ KMP/ Director / Immediate Relatives / Employee / etc
Security Type: Share/ Warrants / Convertible Debentures

Data as reported to USA Exchanges

View All The Insider Trades disclosures

40.70% Fall from 52W High

Insider Trading disclosures for Aardvark Therapeutics Inc.

The latest disclosure was made by Susan E. Graf in Aardvark Therapeutics Inc. where a trade of 30,508 Stock Option (right to buy) done was reported to US exchanges on June 11, 2025.

Screeners based on Insider Trading and SAST parameters